Recombinant Human IL-13 Variant

Molecule:

IL-13

Synonyms:

Interleukin-13, ALRH, BHR1, IL-13

Species:

Human

Cat. No.:

CSI20282C pdf (datasheet)

Quantity/Size:

1.0 mg

Price:

$4,680.00 / Special Price: $2,590.00 BUY

Description:

Recombinant Human IL-13, Variant, is a single non-glycosylated polypeptide chain containing 112 amino acids, with a substitution of Q for R at position 112 compared with the wild type IL-13. Background: Human Interleukin-13 (IL-13) is expressed by the IL13 gene located on the chromosome 5. IL-13 is a 132 amino acid protein containing a proposed 20 amino acid signal peptide, and shares approximately 30% amino acid sequence homology to human IL-4. Additionally, the two cytokines exhibit overlapping biological activities. Human IL-13 is produced by activated Th0, Th1-like Th2-like and CD8 T cells. Similarly to IL-4, IL-13 has multiple effects on the differentiation and functions of monocytes/macrophages. IL-13 can suppress the cytotoxic functions of monocytes/macrophages. IL-13 variant is a natural variant of IL-13 and has a Q instead of R112 of wild type, which associated with increased risk for asthma development and at homozygosity associated with higher levels of serum total IgE in some allergic rhinitis patients.

Entrez Symbol:

IL13

Uniprot Name:

interleukin 13

Data PDF:

CSI20282

Source:

E. coli

Molecular Weight:

Approximately 12.5 kDa, a single non-glycosylated polypeptide chain containing 114 amino acids, with a substitution of Q for R at position 112 compared with the wild type IL-13.

Formulation:

Lyophilized from a 0.2μm filtered concentrated solution in PBS, pH 7.2, containing 5% trehalose.

Purity:

>95% by SDS-PAGE and HPLC analyses.

Biological Activity:

Fully biologically active when compared to standard. The ED50 as determined by a cell proliferation assay using human TF-1 cells is less than 0.5 ng/ml.

Specific Activity:

>2.0 × 106 IU/mg

Endotoxin Level:

Less than 1EU/μg of rHuIL-13 variant as determined by LAL method.

Amino Acid Sequence:

SPGPVPPSTA LRELIEELVN ITQNQKAPLC NGSMVWSINL TAGMYCAALE SLINVSGCSA IEKTQRMLSG FCPHKVSAGQ FSSLHVRDTK IEVAQFVKDL LLHLKKLFRE GQFN

Reconstitution:

Centrifuge vial prior to opening. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/ml. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C.

Storage/Stability:

This lyophilized preparation is stable at 2-4°C, but should be kept desiccated at -20°C for long term storage. Upon reconstitution, the preparation is stable for up to one week at 2-4°C.